These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14713926)

  • 41. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections.
    Jia B; Lu P; Huang W; Li C; Huang A; Zhou X; Zhang W; Wu G; Zhang G
    Chemotherapy; 2010; 56(4):285-90. PubMed ID: 20714145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
    Edwards SJ; Campbell HE; Plumb JM
    Eur J Health Econ; 2006 Mar; 7(1):72-8. PubMed ID: 16429296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
    Hou F; Wu G; Zheng B
    Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
    Tonelli F
    Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seizures related to use of imipenem-cilastatin.
    Lane M; Kania D; Rapp RP
    Am J Health Syst Pharm; 1996 Jul; 53(13):1605-6. PubMed ID: 8809285
    [No Abstract]   [Full Text] [Related]  

  • 46. Imipenem-cilastatin induced pure white cell aplasia.
    Kalambokis G; Vassou A; Bourantas K; Tsianos EV
    Scand J Infect Dis; 2005; 37(8):619-620. PubMed ID: 16138439
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safe use of imipenem/cilastatin in a neonatal intensive care unit.
    Lee SY; Chow CB
    Acta Paediatr Jpn; 1998 Apr; 40(2):186-7. PubMed ID: 9581316
    [No Abstract]   [Full Text] [Related]  

  • 48. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
    Nelson WK; Rayback PA; Quinones R; Giller RH
    Ann Pharmacother; 2002 Sep; 36(9):1360-5. PubMed ID: 12196052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin.
    Guglielmo BJ; Jacobs RA
    Am J Health Syst Pharm; 1996 Sep; 53(17):2097-8. PubMed ID: 8870902
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin.
    Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P
    J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety of imipenem/cilastatin in neurocritical care patients.
    Hoffman J; Trimble J; Brophy GM
    Neurocrit Care; 2009; 10(3):403-7. PubMed ID: 19116700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.
    Brismar B; Akerlund JE; Sjöstedt S; Johansson C; Törnqvist A; Bäckstrand B; Bång H; Andåker L; Gustafsson PO; Darle N; Angerås M; Falk A; Tunevall G; Kasholm-Tengve B; Skau T; Nyström PO; Gasslander T; Hagelbäck A; Olsson-Liljequist B; Eklund AE; Nord CE
    Scand J Infect Dis; 1996; 28(5):507-12. PubMed ID: 8953683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.
    Edwards SJ; Emmas CE; Campbell HE
    Curr Med Res Opin; 2005 May; 21(5):785-94. PubMed ID: 15969878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
    Romanelli G; Cravarezza P
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An unusual case of delayed-type hypersensitivity to ceftriaxone and meropenem.
    Dias de Castro E; Leblanc A; Sarmento A; Cernadas JR
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):225-7. PubMed ID: 26549341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections.
    de Groot HG; Hustinx PA; Lampe AS; Oosterwijk WM
    J Antimicrob Chemother; 1993 Sep; 32(3):491-500. PubMed ID: 8262872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imipenem/cilastatin-induced acute eosinophilic pneumonia.
    Foong KS; Lee A; Pekez M; Bin W
    BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26944380
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations.
    Wu CC; Pai TY; Hsiao FY; Shen LJ; Wu FL
    Ther Drug Monit; 2016 Oct; 38(5):587-92. PubMed ID: 27322166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.